NEW YORK (GenomeWeb News) – The ALS Emergency Treatment Fund and Denovo Biomarkers today announced a partnership to evaluate Denovo's technology to identify patients who may best respond to amyotrophic lateral sclerosis drugs being studied.

The partnership will use Denovo's pharmacogenomic technology in order to identify biomarkers from biological samples from expanded access programs sponsored by ALS-ETF. Biomarkers which can be correlated with patient response to treatments may then be used to identify patient subsets for subsequent trials, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.